Compare Cintas Corporation (CTAS) vs Revvity Inc (RVTY) Price & Performance

Cintas (CTAS) trades at $202.41, up 2.65% on the day, reflecting strong momentum after recent earnings beat. The stock exhibits a bullish technical setup with price above key moving averages. Fundamentally, the company reported Q1 2027 revenue of $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 surpassing estimates. Robust profitability is evident with a net income margin of 17.82% and ROE of 41.25%. Recent news highlights raised fiscal 2027 guidance, signaling management confidence in continued growth driven by organic expansion and margin gains.

The outlook for CTAS remains positive, supported by consistent revenue growth, high profitability, and bullish analyst sentiment with a consensus price target of $234.60. Key opportunities include sustained demand for uniform rental and workplace services, while risks involve elevated valuation multiples and potential economic sensitivity. The stock's current trajectory suggests further upside if execution remains strong, though investors should monitor margin sustainability and competitive pressures.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.